{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:44:51Z","timestamp":1792676691413,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"DOI":"10.1007\/s40272-026-00782-1","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:33:06Z","timestamp":1792675986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Pediatric Chronic Spontaneous Urticaria: Current Evidence and Emerging Therapies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2818-967X","authenticated-orcid":false,"given":"Micol","family":"Tedeschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-1415","authenticated-orcid":false,"given":"Maria Gnarra","family":"Buethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-0159","authenticated-orcid":false,"given":"Gian Luigi","family":"Marseglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-6482","authenticated-orcid":false,"given":"Amelia","family":"Licari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"3","key":"782_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"2","key":"782_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bjd.19561","volume":"184","author":"M Gon\u00e7alo","year":"2021","unstructured":"Gon\u00e7alo M, Gim\u00e9nez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226\u201336. https:\/\/doi.org\/10.1111\/bjd.19561.","journal-title":"Br J Dermatol"},{"issue":"2","key":"782_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J, \u00c1vila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423\u201332. https:\/\/doi.org\/10.1111\/all.14037.","journal-title":"Allergy"},{"issue":"6","key":"782_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/pai.12910","volume":"29","author":"MM Balp","year":"2018","unstructured":"Balp MM, Weller K, Carboni V, et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. 2018;29(6):630\u20136. https:\/\/doi.org\/10.1111\/pai.12910.","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"782_CR5","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.jaip.2023.02.022","volume":"11","author":"R Asero","year":"2023","unstructured":"Asero R, Ferrer M, Kocaturk E, Maurer M. Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy. J Allergy Clin Immunol Pract. 2023;11(8):2302\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.022.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"782_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.23822\/EurAnnACI.1764-1489.307","volume":"55","author":"R Asero","year":"2023","unstructured":"Asero R, Tedeschi A. Chronic spontaneous urticaria: from the hunt for causes and pathogenesis to the identification of different endotypes. Eur Ann Allergy Clin Immunol. 2023;55(6):253\u201360. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.307.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"3","key":"782_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report. Allergy. 2011;66(3):317\u201330. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02496.x.","journal-title":"Allergy"},{"issue":"6","key":"782_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70132","volume":"36","author":"O Alomari","year":"2025","unstructured":"Alomari O, Ozceker D, Mokresh ME, et al. Omalizumab in pediatric chronic spontaneous urticaria: a systematic review and meta-analysis of efficacy and safety. Pediatr Allergy Immunol. 2025;36(6):e70132. https:\/\/doi.org\/10.1111\/pai.70132.","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"782_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamadermatol.2025.6023","volume":"162","author":"TB Casale","year":"2026","unstructured":"Casale TB, Saini SS, Ben-Shoshan M, et al. Dupilumab in patients with chronic spontaneous urticaria: phase 3 LIBERTY-CSU CUPID randomized clinical trials. JAMA Dermatol. 2026;162(4):350\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2025.6023.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"782_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"782_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014794","volume":"6","author":"S Altrichter","year":"2011","unstructured":"Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase: a novel pathomechanism of chronic spontaneous urticaria? PLoS ONE. 2011;6(4):e14794. https:\/\/doi.org\/10.1371\/journal.pone.0014794.","journal-title":"PLoS ONE"},{"issue":"3","key":"782_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/cei.13428","volume":"200","author":"R Asero","year":"2020","unstructured":"Asero R, Marzano AV, Ferrucci S, et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200(3):242\u20139. https:\/\/doi.org\/10.1111\/cei.13428.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"782_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2222.1991.tb03198.x","volume":"21","author":"CEH Grattan","year":"1991","unstructured":"Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21(6):695\u2013704. https:\/\/doi.org\/10.1111\/j.1365-2222.1991.tb03198.x.","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"782_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jaci.2006.08.043","volume":"119","author":"R Asero","year":"2007","unstructured":"Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol. 2007;119(3):705\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2006.08.043.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"782_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jid.2020.06.030","volume":"141","author":"M Shtessel","year":"2021","unstructured":"Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria. J Invest Dermatol. 2021;141(3):678-81.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.06.030.","journal-title":"J Invest Dermatol"},{"key":"782_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1272230","volume":"16","author":"O Mahmoud","year":"2023","unstructured":"Mahmoud O, Oladipo O, Mahmoud RH, Yosipovitch G. Itch: from the skin to the brain: peripheral and central neural sensitization in chronic itch. Front Mol Neurosci. 2023;16:1272230. https:\/\/doi.org\/10.3389\/fnmol.2023.1272230.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"782_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaci.2025.05.011","volume":"156","author":"MK Jha","year":"2025","unstructured":"Jha MK, Han Y, Liu Z, et al. Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch. J Allergy Clin Immunol. 2025;156(4):1066-81.e12. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"782_CR18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.jaip.2022.02.033","volume":"10","author":"S Gabrielli","year":"2022","unstructured":"Gabrielli S, Mul\u00e9 P, Prosty C, et al. Validation of UAS7 among children with chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2022;10(7):1927-9.e1. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.033.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"782_CR19","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.jaip.2022.07.037","volume":"10","author":"C Prosty","year":"2022","unstructured":"Prosty C, Gabrielli S, Mule P, et al. Validation of the Urticaria Control Test (UCT) in children with chronic urticaria. J Allergy Clin Immunol Pract. 2022;10(12):3293-8.e2. https:\/\/doi.org\/10.1016\/j.jaip.2022.07.037.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000546466","volume":"187","author":"CK Zhu","year":"2026","unstructured":"Zhu CK, Benharira N, Prosty C, et al. Assessment of quality of life in children with chronic urticaria using the Children\u2019s Dermatology Life Quality Questionnaire Index: a retrospective cohort study. Int Arch Allergy Immunol. 2026;187:51\u201360. https:\/\/doi.org\/10.1159\/000546466.","journal-title":"Int Arch Allergy Immunol"},{"key":"782_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljag121","author":"E Kocat\u00fcrk","year":"2026","unstructured":"Kocat\u00fcrk E, Grattan C, Cherrez I, et al. The overall burden of chronic spontaneous urticaria: the current landscape. Br J Dermatol. 2026. https:\/\/doi.org\/10.1093\/bjd\/ljag121.","journal-title":"Br J Dermatol"},{"issue":"25","key":"782_CR22","doi-asserted-by":"publisher","first-page":"00646","DOI":"10.1016\/j.jaci.2025.06.018","volume":"S0091\u20136749","author":"AWL Chu","year":"2025","unstructured":"Chu AWL, Oykhman P, Chu X, et al. Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: systematic review and network meta-analysis. J Allergy Clin Immunol. 2025;S0091\u20136749(25):00646\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2025.06.018.","journal-title":"J Allergy Clin Immunol"},{"key":"782_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","author":"T Zuberbier","year":"2026","unstructured":"Zuberbier T, Abdul Hameed Ansari Z, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70210.","journal-title":"Allergy"},{"issue":"4","key":"782_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","volume":"65","author":"MK Church","year":"2010","unstructured":"Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65(4):459\u201366. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02325.x.","journal-title":"Allergy"},{"issue":"4","key":"782_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaad.2015.06.048","volume":"73","author":"M Sharma","year":"2015","unstructured":"Sharma M, Bennett C, Carter B, Cohen SN. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane systematic review. J Am Acad Dermatol. 2015;73(4):710-16.e4. https:\/\/doi.org\/10.1016\/j.jaad.2015.06.048.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"782_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/pai.13325","volume":"32","author":"L Sarti","year":"2021","unstructured":"Sarti L, Barni S, Giovannini M, et al. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153\u201360. https:\/\/doi.org\/10.1111\/pai.13325.","journal-title":"Pediatr Allergy Immunol"},{"key":"782_CR27","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic spontaneous urticaria: a review. JAMA. 2024;332:1464\u201377. https:\/\/doi.org\/10.1001\/jama.2024.15568.","journal-title":"JAMA"},{"issue":"2","key":"782_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S1081-1206(10)62457-X","volume":"85","author":"R Asero","year":"2000","unstructured":"Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol. 2000;85(2):156\u20137. https:\/\/doi.org\/10.1016\/S1081-1206(10)62457-X.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"782_CR29","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jaci.2024.05.026","volume":"154","author":"DG Rayner","year":"2024","unstructured":"Rayner DG, Liu M, Chu AWL, et al. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2024;154(4):996\u20131007. https:\/\/doi.org\/10.1016\/j.jaci.2024.05.026.","journal-title":"J Allergy Clin Immunol"},{"key":"782_CR30","unstructured":"Singulair (montelukast sodium) [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.; 2020."},{"issue":"3","key":"782_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.5429","volume":"179","author":"V Wintzell","year":"2025","unstructured":"Wintzell V, Ludvigsson JF, Pasternak B, et al. Montelukast use and the risk of neuropsychiatric adverse events in children. JAMA Pediatr. 2025;179(3):e245429. https:\/\/doi.org\/10.1001\/jamapediatrics.2024.5429.","journal-title":"JAMA Pediatr"},{"issue":"5","key":"782_CR32","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","volume":"151","author":"LG Presta","year":"1993","unstructured":"Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623\u201332. https:\/\/doi.org\/10.4049\/jimmunol.151.5.2623.","journal-title":"J Immunol"},{"issue":"24","key":"782_CR33","doi-asserted-by":"publisher","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","volume":"292","author":"AM Davies","year":"2017","unstructured":"Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975\u201387. https:\/\/doi.org\/10.1074\/jbc.M117.776476.","journal-title":"J Biol Chem"},{"issue":"3","key":"782_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/14712598.2017.1285903","volume":"17","author":"AM Gim\u00e9nez-Arnau","year":"2017","unstructured":"Gim\u00e9nez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17(3):375\u201385. https:\/\/doi.org\/10.1080\/14712598.2017.1285903.","journal-title":"Expert Opin Biol Ther"},{"key":"782_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","volume":"137","author":"A Kaplan","year":"2016","unstructured":"Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2015.08.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"782_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.15030","volume":"77","author":"I Agache","year":"2022","unstructured":"Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines: omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12\u201317 years old. Allergy. 2022;77(1):17\u201338. https:\/\/doi.org\/10.1111\/all.15030.","journal-title":"Allergy"},{"key":"782_CR37","unstructured":"Genentech, Inc. Xolair\u00ae (omalizumab) injection, for subcutaneous use: US prescribing information. South San Francisco (CA): Genentech, Inc.; 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103976s5245lbl.pdf. Accessed 27 Sep 2026."},{"key":"782_CR38","unstructured":"European Medicines Agency. Xolair\u00ae (omalizumab): EPAR product information. Amsterdam: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_en.pdf. Accessed 27 Sep 2026."},{"issue":"1","key":"782_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67\u201375. https:\/\/doi.org\/10.1038\/jid.2014.306.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"782_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1215372.","journal-title":"N Engl J Med"},{"issue":"1","key":"782_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"782_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13489","volume":"33","author":"S Passanisi","year":"2020","unstructured":"Passanisi S, Arasi S, Caminiti L, et al. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33(4):e13489. https:\/\/doi.org\/10.1111\/dth.13489.","journal-title":"Dermatol Ther"},{"issue":"6","key":"782_CR43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/pde.14360","volume":"37","author":"A Ari","year":"2020","unstructured":"Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37(6):1051\u20134. https:\/\/doi.org\/10.1111\/pde.14360.","journal-title":"Pediatr Dermatol"},{"key":"782_CR44","unstructured":"Celltrion, Inc. Omlyclo\u00ae (omalizumab-igec) injection, for subcutaneous use: US prescribing information. Jersey City (NJ): Celltrion USA, Inc.; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761399s000lbl.pdf. Accessed 29 Jul 2026."},{"key":"782_CR45","unstructured":"US Food and Drug Administration. Omlyclo (omalizumab-igec), BLA 761399: approval letter. Silver Spring (MD): US Food and Drug Administration; 7 March 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/761399Orig1s000ltr.pdf. Accessed 29 Jul 2026."},{"key":"782_CR46","unstructured":"European Medicines Agency. Omlyclo: EPAR product information. Amsterdam: European Medicines Agency; 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/omlyclo.  Accessed 10 Oct 2026."},{"key":"782_CR47","unstructured":"A study to investigate the pharmacokinetics and safety of dupilumab in participants \u2265\u20092 years to <\u200912 years of age with uncontrolled chronic spontaneous urticaria (CSU) (LIBERTY-CSU CUPIDKids). https:\/\/clinicaltrials.gov\/study\/NCT05526521. Accessed 29 Jul 2026."},{"key":"782_CR48","unstructured":"Regeneron Pharmaceuticals, Inc. Dupixent\u00ae (dupilumab) injection, for subcutaneous use: US prescribing information. Tarrytown (NY): Regeneron Pharmaceuticals, Inc.; 2025. Revised June 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761055s070lbl.pdf. Accessed 10 Oct 2026."},{"key":"782_CR49","unstructured":"European Medicines Agency. Dupixent\u00ae (dupilumab): EPAR: product information. Amsterdam: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 30 Jul 2026."},{"issue":"5","key":"782_CR50","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1523-1747.ep12499960","volume":"98","author":"C Stellato","year":"1992","unstructured":"Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol. 1992;98(5):800\u20134. https:\/\/doi.org\/10.1111\/1523-1747.ep12499960.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"782_CR51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1525-1470.2009.00869.x","volume":"26","author":"DR Doshi","year":"2009","unstructured":"Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409\u201313. https:\/\/doi.org\/10.1111\/j.1525-1470.2009.00869.x.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"782_CR52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jaip.2014.04.011","volume":"2","author":"L Neverman","year":"2014","unstructured":"Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract. 2014;2(4):434\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2014.04.011.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"782_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2340\/00015555-0939","volume":"91","author":"C Boubouka","year":"2011","unstructured":"Boubouka C, Charissi C, Kouimintzis D, et al. Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up. Acta Derm Venereol. 2011;91(1):50\u20134. https:\/\/doi.org\/10.2340\/00015555-0939.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"782_CR54","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/cea.12400","volume":"44","author":"JP Arm","year":"2014","unstructured":"Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371\u201385. https:\/\/doi.org\/10.1111\/cea.12400.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"782_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13982","volume":"34","author":"P Staubach","year":"2023","unstructured":"Staubach P, Alvaro-Lozano M, Sekerel BE, et al. Ligelizumab in adolescents with chronic spontaneous urticaria: results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatr Allergy Immunol. 2023;34(2):e13982. https:\/\/doi.org\/10.1111\/pai.13982.","journal-title":"Pediatr Allergy Immunol"},{"issue":"10422","key":"782_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","volume":"403","author":"M Maurer","year":"2024","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials (PEARL-1 and PEARL-2). Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","journal-title":"Lancet"},{"issue":"15","key":"782_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157765","volume":"132","author":"BS Kuo","year":"2022","unstructured":"Kuo BS, Li CH, Chen JB, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Investig. 2022;132(15):e157765. https:\/\/doi.org\/10.1172\/JCI157765.","journal-title":"J Clin Investig"},{"issue":"6","key":"782_CR58","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.jaci.2016.06.023","volume":"138","author":"JM Harris","year":"2016","unstructured":"Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;138(6):1730\u20132. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"782_CR59","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","volume":"155","author":"J McLaren","year":"2025","unstructured":"McLaren J, Chon Y, Gorski KS, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025;155(6):1945\u201356. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.045.","journal-title":"J Allergy Clin Immunol"},{"key":"782_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101826","volume":"57","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023;57:101826. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101826.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"782_CR61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.18176\/jiaci.0770","volume":"33","author":"L Antonicelli","year":"2023","unstructured":"Antonicelli L, Tontini C, Garritani MS, Piga MA, Bil\u00f2 MB. Efficacy of mepolizumab in patients with severe eosinophilic asthma and concomitant severe chronic urticaria: an example of personalized medicine? J Investig Allergol Clin Immunol. 2023;33(1):54\u20136. https:\/\/doi.org\/10.18176\/jiaci.0770.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"782_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/ddg.13481","volume":"16","author":"M Magerl","year":"2018","unstructured":"Magerl M, Terhorst D, Metz M, Altrichter S, Zuberbier T, Maurer M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges. 2018;16(4):477\u20138. https:\/\/doi.org\/10.1111\/ddg.13481.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"782_CR63","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/jdv.14594","volume":"32","author":"M Maurer","year":"2018","unstructured":"Maurer M, Altrichter S, Metz M, Zuberbier T, Church MK, Bergmann KC. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol. 2018;32(3):e112\u20133. https:\/\/doi.org\/10.1111\/jdv.14594.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"782_CR64","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1111\/jdv.15720","volume":"33","author":"KC Bergmann","year":"2019","unstructured":"Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019;33(11):e413\u20135. https:\/\/doi.org\/10.1111\/jdv.15720.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"782_CR65","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaip.2020.07.058","volume":"9","author":"JT Maul","year":"2021","unstructured":"Maul JT, Distler M, Kolios A, et al. Canakinumab lacks efficacy in treating adult patients with moderate to severe chronic spontaneous urticaria in a phase II randomized double-blind placebo-controlled single-center study. J Allergy Clin Immunol Pract. 2021;9(1):463-8.e3. https:\/\/doi.org\/10.1016\/j.jaip.2020.07.058.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"782_CR66","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/cea.13616","volume":"50","author":"DA Sabag","year":"2020","unstructured":"Sabag DA, Matanes L, Bejar J, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(7):799\u2013804. https:\/\/doi.org\/10.1111\/cea.13616.","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"782_CR67","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/all.16598","volume":"80","author":"M Maurer","year":"2025","unstructured":"Maurer M, Metz M, Anderson J, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025;80(8):2178\u201386. https:\/\/doi.org\/10.1111\/all.16598.","journal-title":"Allergy"},{"key":"782_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.02.018","author":"M Metz","year":"2026","unstructured":"Metz M, Mitha E, Leflein J, et al. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2026. https:\/\/doi.org\/10.1016\/j.jaci.2026.02.018.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"782_CR69","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","volume":"149","author":"S Altrichter","year":"2022","unstructured":"Altrichter S, Staubach P, Pasha M, et al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. 2022;149(5):1683-90.e7. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.772.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"782_CR70","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.iac.2024.03.008","volume":"44","author":"M Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz M, Kocat\u00fcrk E, Maurer M, Kolkhir P. Emerging therapeutics in chronic urticaria. Immunol Allergy Clin North Am. 2024;44(3):517\u201358. https:\/\/doi.org\/10.1016\/j.iac.2024.03.008.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"11","key":"782_CR71","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","volume":"27","author":"M Metz","year":"2021","unstructured":"Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01537-w.","journal-title":"Nat Med"},{"issue":"6","key":"782_CR72","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498-506.e2. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"782_CR73","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2408792.","journal-title":"N Engl J Med"},{"issue":"2","key":"782_CR74","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","volume":"153","author":"V Jain","year":"2024","unstructured":"Jain V, Gim\u00e9nez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol. 2024;153(2):479-86.e4. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"782_CR75","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","volume":"161","author":"A Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau A, Ferrucci S, Ben-Shoshan M, et al. Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial. JAMA Dermatol. 2025;161(6):679\u201387. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0733.","journal-title":"JAMA Dermatol"},{"key":"782_CR76","doi-asserted-by":"publisher","first-page":"AB226","DOI":"10.1016\/j.jaci.2024.12.696","volume":"155","author":"A Fukunaga","year":"2025","unstructured":"Fukunaga A, Yagami A, Hide M. Bruton\u2019s tyrosine kinase inhibitor TAS5315 improved pruritus- and wheal-free days in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2025;155:AB226. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.696.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"782_CR77","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"782_CR78","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2340\/00015555-3006","volume":"98","author":"A Fukunaga","year":"2018","unstructured":"Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98(9):904\u20135. https:\/\/doi.org\/10.2340\/00015555-3006.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"782_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15932","volume":"35","author":"P Mansouri","year":"2022","unstructured":"Mansouri P, Mozafari N, Chalangari R, Martits-Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022;35(1):e15932. https:\/\/doi.org\/10.1111\/dth.15932.","journal-title":"Dermatol Ther"},{"issue":"4","key":"782_CR80","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","volume":"154","author":"J Wollam","year":"2024","unstructured":"Wollam J, Solomon M, Villescaz C, et al. Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol. 2024;154(4):1033\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"782_CR81","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","volume":"151","author":"M Kumar","year":"2023","unstructured":"Kumar M, Duraisamy K, Annapureddy RR, Chan CB, Chow BKC. Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction. J Allergy Clin Immunol. 2023;151(4):1110\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.805.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00782-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:33:08Z","timestamp":1792675988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00782-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":81,"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00782-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Micol Tedeschi, Maria Gnarra Buethe, Gian Luigi Marseglia, and Amelia Licari have no conflicts of interests that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. No ethics approval was required for this narrative review.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No custom code or software was developed or used for this narrative review.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of the review. MT performed the literature search and data synthesis and drafted the manuscript. MGB, GLM, and AL contributed to the literature review and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}